HBMA Washington Report – October Issue

Washington Report – October 2018
(Covers activity between 10/1/18 and 10/31/18)
Bill Finerfrock, Matt Reiter, and Carolyn Bounds

Download: Washington Report October Issue

  • 2019 Medicare Physician Fee Schedule Final Rule Scales Back Proposed E/M Coding Changes
  • Medicare Physician Fee Schedule Finalizes Many Provisions from Proposed Rule
  • CMS Finalizes 2019 MIPS Requirements
  • Open Enrollment Begins for ACA Exchanges
  • OPPS Final Rule Expands Site-Neutral Payment Policy
  • Senators Introduce New Surprise Billing Legislation
  • Trump Administration Revises Guidelines for ACA Section 1332 Waivers
  • Trump Administration Announces Proposed Overhaul Part B Drug Payment Methodology
  • CMS to Host National Provider Enrollment Conference in March
  • Trump Administration Targets Drug Prices in Series of Actions
  • CMS Announces 2019 Medicare Premiums and Deductibles
  • CMS Transmittals

 

HBMA Washington Report – September Issue

Washington Report – September 2018
(Covers activity between 9/1/18 and 9/30/18)
Bill Finerfrock, Matt Reiter, and Carolyn Bounds

Download: Washington Report September Issue

  • HBMA Recommends Improvements to the CMS Targeted Probe and Educate Process
  • CMS Makes Major Updates to LCD Development Process
  • CMS Issues MIPS Payment Adjustment Corrections
  • Congress Passes FY 2019 Government Funding Bills
  • Senator Introduces Bill to Limit Surprise Bills for Emergency Care
  • CAQH CORE Publishes Updates to CARC/RARC Code Combinations
  • Congress Passes Sweeping Legislation to Address Opioid Crisis
  • CMS Proposes Technical Changes to Appeals Process to Improve Procedural Consistency
  • High MA Appeal Overturn Rate Implies Improper Denial Practices
  • CMS Improves Online Medicare Enrollment for Beneficiaries
  • House Passes Medicare Smart Card Demonstration Bill
  • CMS Issues Report on RAC Performance in 2016
  • Social Security Number Removal Initiative Update
  • CMS Transmittals

 

HBMA Washington Report – August Issue

Washington Report – August 2018
(Covers activity between 8/1/18 and 8/31/18)
Bill Finerfrock, Matt Reifer, and Carolyn Bounds

Download: Washington Report August Issue

  • Medicare Inpatient Payment Final Rule Indicates Changes Coming to Physician Reimbursements
  • House Ways and Means Committee Advances Bills on Medicare Smart Cards and LCD Transparency
  • CDC Survey Shows Decline in Uninsured Rate
  • House Ways and Means Committee Recommends Regulatory Relief Actions to CMS
  • HHS Making Progress in Reducing Backlog of Appealed Claims
  • Senate Passes HHS Spending Bill Setting up Negotiations on Final Version with House
  • Social Security Number Removal Initiative Update
  • CMS Publishes 2017 ACO Performance Data
  • CMS Transmittals

 

HBMA Washington Report – July Issue

Washington Report – July, 2018
(Covers activity between 7/1/18 and 7/31/18)
Bill Finerfrock, Matt Reiter, and Carolyn Bounds

Download: Washington Report July Issue

  • CMS Releases 2019 Medicare Physician Fee Schedule Proposed Rule
  • Administration Proposes Major Changes to Evaluation and Management Coding
  • CMS Proposes 2019 MIPS Reporting Year Requirements
  • CMS Soliciting Public Feedback on Price Transparency and EHR Interoperability
  • CMS Extends Deadline for Requesting Appeal of 2017 MIPS Performance Score
  • House of Representatives Passes Package of Healthcare Bills
  • CMS Proposes Expanding Site Neutral Payments for Hospital Outpatient Services
  • PFS Includes Demonstration for Medicare Advantage MIPS Exemption
  • Despite Proposed MIPS Changes, Stakeholders Say More Improvements are Needed
  • Social Security Number Removal Initiative Update
  • CMS Transmittals

HBMA Washington Report – June Issue

Washington Report – June, 2018
(Covers activity between 6/1/18 and 6/30/18)
Bill Finerfrock, Matt Reiter, Sarah Wilson and Carolyn Bounds

Washington Report – June Issue

  • HBMA GR Committee Holds Annual Visit to CMS and Washington, D.C.
  • 2017 MIPS Performance Feedback is Available via EIDM Accounts
  • CAQH Index Shows Billions in Potential Savings Remain from Transition to Electronic   Transactions
  • Department of Labor Issues Association Health Plan Final Rule
  • Social Security Number Removal Initiative Update
  • CMS Publishes FY 2019 ICD-10-CM Diagnosis Codes
  • CMS to Again Include QMB Status on Remittance Advice
  • CMS Publishes 2017 Open Payments Data
  • HHS Throws Cold Water on Physician-Focused Payment Models
  • CMS Solicits Public Input on how to Reform Physician Self-referral Law
  • MedPAC Suggests Ten Percent Increase for E&M Payments
  • 2018 Trustees Report Projects Accelerated Timeline for Hospital Trust Fund Insolvency
  • House Passes Series of Opioid Bills
  • CMS Creates First Medicaid and CHIP “Scorecard”
  • DOJ Boasts Largest Annual Fraud Takedown to Date
  • Federal Court Blocks Kentucky’s Medicaid Work Requirement
  • CMS Transmittals

CMS Signals Willingness to Revamp Stark for Coordinated Care Efforts

By Kristin M. Bohl and Samantha C. Flanzer

CMS issued a Request for Information (RFI), seeking input from the public on how best to address and mitigate any “undue regulatory impact and burden” of the physician self-referral law (“Stark Law”). The RFI, filed on June 20, 2018, signals a willingness on the part of CMS to consider revisions of the Stark Law to accommodate new payment models. While the RFI is largely focused on the intersection of the Stark Law and care coordination models, it also seeks public input on potential changes to core tenants of the Stark Law – e.g., regarding the definition of “commercial reasonableness” and when compensation should be considered to “take into account other business generated” between parties to an arrangement.

Highlights of those areas CMS is requesting public input include:

  • To what extent the Stark Law currently impacts commercial alternative payment models, and to what extent additional Stark Law exceptions may be necessary to protect such arrangements;
  • The current utility of the risk-sharing arrangement Stark Law exception;
  • To what extent it may be prudent for CMS to add a “special rule for compensation under a physician incentive plan” within the current Stark Law personal services arrangements exception;
  • Possible approaches to defining “commercial reasonableness” and “fair market value”;
  • When compensation should be considered to “take into account the volume or value of referrals” by a physician or “take into account other business generated” between parties to an arrangement (both inside and outside the context of alternative payment models);
  • What barriers exist to qualifying as a “group practice” under the Stark Law;
  • How CMS could interpret the exception for remuneration unrelated to designated health services (DHS) to cover a broader array of arrangements; and
  • The role of transparency in the context of the Stark Law, (e.g., how transparency about a physician’s financial relationship may reduce or eliminate harms to the Medicare program and its beneficiaries that the Stark Law is intended to address).

While this is certainly not the first time CMS has requested public input on potential revamps to the Stark Law, this RFI may nonetheless signal increasing momentum for Stark Law reform within the government.

READ MORE


About the Authors

Kristin M. Bohl
Baltimore
410.862.1145
kbohl@bakerdonelson.com

Samantha C. Flanzer
Baltimore
410.862.1077
sflanzer@bakerdonelson.com

June Washington, D.C. Update

Heading into the summer, Congress has remained focused on completing the national defense authorization bill, appropriations for Fiscal Year 2019 (FY 2019), and advancing legislation to address opioid abuse. Lawmakers are eager to demonstrate action prior to the upcoming midterm elections, prompting Senate Majority Leader Mitch McConnell (R-KY) to issue a statement canceling the majority of the Senate’s August recess. At the same time, the Trump Administration continues to generate major news on immigration, foreign policy, and trade, including the recent high-profile summit between President Trump and North Korea’s Kim Jong-un and new tariffs announced on China, the European Union, Canada, and Mexico. The Administration has also continued to promote its drug-pricing plan and recently released new widely anticipated regulations on association health plans.

In this month’s Washington, D.C. Update, we examine:

Please feel free to reach out for additional information on these topics or other issues of importance.

Sheila Burke
Chair, Government Relations and Public Policy
Baker Donelson


Senate Passes Defense Authorization Bill, Including Penalties on China’s ZTE and New Authority for CFIUS

On June 18, the U.S. Senate voted 85-10 to approve the annual National Defense Authorization Act (NDAA), authorizing a total of $716 billion in Fiscal Year 2019 (FY 2019) for national defense. The NDAA authorizes a base defense budget of $639 billion for the Department of Defense and national security programs at the Department of Energy. The NDAA also authorizes $69 billion for Overseas Contingency Operations. Next, a joint conference committee will meet to resolve differences between the House and Senate bills, a process House Armed Services Committee Chairman Mac Thornberry (R-TX) hopes to finish by the end of July. However, many observers do not expect final resolution until the end of the year.

READ MORE


Trump Administration Releases Regulations to Expand Association Health Plans

On June 19, the Department of Labor (DOL) released a final rule to expand access to association health plans (AHPs), which allow employers to form groups to collectively purchase health coverage for their employees. The new AHPs will not be subject to the full coverage or non-discrimination requirements under the Affordable Care Act (ACA), allowing these plans more flexibility on benefit designs and premiums. The Administration and Republican lawmakers argue that expanding AHPs will provide cheaper alternatives for small businesses and self-employed individuals that have struggled to find affordable options in the ACA’s insurance exchanges. However, Democrats, state regulators, and many health care stakeholders warn that expanding AHPs is likely to drive up premiums in the ACA’s insurance exchanges by siphoning off younger and healthier consumers.

Baker Donelson issued an overview of the new regulations on AHPs on June 20, available here.

The Congressional Budget Office estimates that the new regulations will result in approximately four million additional individuals enrolling in AHPs by 2023, including approximately 400,000 previously uninsured individuals. However, CBO also projects that due to the new regulations on AHPs and Short-Term Limited Duration Insurance Plans, average premiums will increase two to three percent in the ACA insurance exchanges.


House Passes First Appropriations Bills of the Cycle; Rescissions Package Passes House, Senate Prospects Unclear

On Friday, June 8, the House passed a roughly $147 billion three-bill FY 2019 spending package on a 235 to 179 vote, overcoming Democratic objections to environmental policy riders and funding priorities in the GOP-drafted Energy-Water title. The “minibus,” which also includes the Military Construction-VA and Legislative Branch measures, is the first of what House GOP leaders expect to be a series of three-bill packages to try to expedite passage of at least a few of the 12 annual spending bills before the end of the fiscal year on September 30. On final passage, 16 Republicans crossed the aisle to vote “no” on the package, but these votes were outweighed by 23 Democratic votes in favor of the minibus.

READ MORE


Opioids Focus in Congress: House Passes Dozens of Opioids Bills; Senate Finance and HELP Committees Advance Draft Legislation

Given broad interest in addressing opioid abuse and growing public pressure, both the House and Senate are considering a broad range of bills designed to address opioids, with lawmakers working to pass legislation during the summer to demonstrate action before the midterm elections.

The House passed 39 opioids-related bills last week, including incremental measures to reduce excess and unused prescription opioids in circulation, increase access to addiction treatment and alternative pain treatments, restrict imported fentanyl arriving through international mail, and expand coverage for telehealth treatment for substance use disorder. The House advanced most of the bills by a voice vote. On June 14, Ways and Means Committee Chairman Kevin Brady (R-TX) and Ranking Member Richard Neal (D-MA), and Energy and Commerce Committee Chairman Greg Walden (R-OR) and Ranking Member Frank Pallone Jr. (D-NJ) introduced H.R. 6, the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act. House Leadership intends for H.R. 6 to serve as the underlying vehicle for the majority of House-passed bills on opioids. The House has continued voting on dozens of additional proposals this week and aims to wrap up the focus on opioids legislation, including voting on H.R. 6, by the end of the week.

READ MORE


Azar Targets Drug Rebates and Medicare Part B for Drug Pricing Policy Changes

Health and Human Services (HHS) Secretary Alex Azar has continued to promote and expand on the Trump Administration’s new Drug Pricing Blueprint through media appearances and congressional testimonies over the past several weeks.

In a Senate Health, Education, Labor and Pensions (HELP) Committee hearing on June 12, Azar called particular attention to the idea of eliminating drug rebates to pharmacy benefit managers (PBMs) and encouraging a pricing system “where PBMs and drug companies just negotiate fixed-price contracts.” Under the current system, drug manufacturers set initial list prices and PBMs negotiate discounts or rebates down from those list prices. Azar contended that eliminating drug rebates and using fixed-price discounts would better incentivize companies to set lower list prices. Azar believes HHS has the regulatory authority to eliminate rebates in Medicare Part D. Replacing the drug rebate system with a fixed-price contract system may have major implications for the drug industry. There is uncertainty regarding the details of how a fixed-price contract system would operate and whether the Trump Administration could implement such a change without Congress.

READ MORE


Trade Tensions Escalate After Trump Administration Imposes Steel and Aluminum Tariffs on Allies and Technology Tariffs on China

On Thursday, May 31, President Trump announced he would impose tariffs on imported steel and aluminum from the European Union, Canada, and Mexico, triggering immediate retaliation from U.S. allies and protests from American businesses and farmers. The tariffs – 25 percent on steel and 10 percent on aluminum – took effect at midnight that night, marking a major escalation of the tension between the United States and its top trading partners. Stung by the U.S. action, the allies quickly hit back. The E.U. stated it would impose import taxes on politically sensitive items like bourbon from Senate Majority Leader Mitch McConnell’s home state of Kentucky. Mexico said it would levy tariffs on American farm products, while Canada zeroed in on the same metals that Trump had targeted.

READ MORE


Department of Justice’s Stance on Legal Challenge to ACA Reignites Fight over Protections for Pre-Existing Conditions

On June 7, the Department of Justice (DOJ) filed a legal brief in support of a lawsuit from 20 states seeking to invalidate the Affordable Care Act (ACA), urging the federal court considering the case to strike down the ACA’s protections for pre-existing conditions. The Texas-led lawsuit, Texas v. United States Department of Health and Human Services, claims that Congress’s recent elimination of the ACA’s individual mandate penalty means that the individual mandate is now unconstitutional. As a result, the plaintiffs argue that the entire statute is now invalid because the individual mandate is central to the law. The Trump Administration agreed in its filing that the individual mandate is unconstitutional and claims that the federal court should also strike down the ACA’s guaranteed issue and community rating provisions because those provisions are too closely tied to the individual mandate. In a letter to House Speaker Paul Ryan, Attorney General Jeff Sessions acknowledged that the executive branch typically defends existing federal law, but stated that this is a “rare case where the proper course” is to forgo a defense.

READ MORE


Dodd-Frank Law Loosened by the House; Volcker Rule Changes Proposed by the Fed

On May 22, by a vote of 258-159, the House approved a Senate-passed bill to free thousands of small and medium-sized banks from strict rules that had been enacted in 2010 as part of the Dodd-Frank law intended to prevent another financial crisis. The bipartisan passage in both the House and the Senate handed a significant victory to President Trump, who promised to undo the Dodd-Frank regulations. The bill stopped short of unwinding the toughened regulatory regime put in place to prevent the nation’s biggest banks from engaging in risky behavior, but it still represents a substantial change to the Obama-era rules governing a large swath of the banking system. The legislation will leave fewer than ten big banks in the United States subject to stricter federal oversight, freeing thousands of banks with less than $250 billion in assets from the restrictions.

READ MORE


About the Authors

Sheila P. Burke
Washington, D.C.
202.508.3457
sburke@bakerdonelson.com

Sam E. Sadle
Washington, D.C.
202.508.3476
ssadle@bakerdonelson.com

Amit Rao
Washington, D.C.
202.508.3472
arao@bakerdonelson.com

HBMA Washington Report – May Issue

Washington Report – May, 2018
(Covers activity between 5/1/18 and 5/31/18)
Bill Finerfrock, Matt Reiter, Sarah Wilson and Carolyn Bounds

Washington Report – May Issue

  • HBMA Participates in NCVHS Healthcare Transaction Forum
  • CMS Publishes 2019 ICD-10 PCS Updates
  • CAQH CORE Releases Newest CARC and RARC Combinations
  • Congress Passes VA Choice Program Reform Bill
  • 91 Percent of Eligible Clinicians Participated in QPP in 2017
  • GAO Recommends that CMS Continue its Prior Authorization Initiatives
  • HHS Releases List of Upcoming Regulations
  • Five New MedPAC Commissioners Selected
  • CMS Announces New Rural Health Strategy
  • White House Unveils Plan to Address Rising Prescription Drug Prices
  • GAO Report Finds Limited Success for New Medicare Payment Models
  • CMS Rejects Lifetime Caps for Medicaid
  • GAO Study of State Laws on Medical Record Transfer Fees
  • CMS Transmittals

GOVERNMENT RELATIONS AND PUBLIC POLICY

President Trump Releases Drug Pricing Blueprint

By Sheila Burke, Niki Carelli, Tiffani Williams, Jeff Davis, and Amit Rao

On Friday, May 11, President Donald Trump and Department of Health and Human Services (HHS) Secretary Alex Azar presented the Administration’s long-awaited plan to address drug pricing. The proposed framework, entitled, “American Patients First: The Trump Administration Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs” aims to achieve four goals:

  • Increase competition for generic and biosimilar drugs;
  • Improve drug price negotiation in Medicare Part B and Part D;
  • Provide incentives for drug manufacturers to lower list prices; and
  • Reduce consumer out-of-pocket spending.

While the blueprint is fairly high-level and will require additional administrative and congressional action over time to implement, the proposed plan represents a pivotal step in the drug pricing debate and opens the door for stakeholders to weigh-in on the proposed policies. To that end, on May 14, HHS issued a Request for Information (RFI) on dozens of drug pricing proposals with a 60-day comment period.

READ MORE


HHS Solicits Comments on Possible 340B Program Changes to Reduce Drug Prices

By Jeff Davis, Sheila Burke, and Amit Rao

The Department of Health and Human Services (HHS) is soliciting comments from the public on the Administration’s proposals to reduce drug prices and is targeting the 340B drug pricing program as an area of focus. The 340B program requires drug manufacturers to sell outpatient drugs at discounted rates to certain public and non-profit hospitals that treat high volumes of low-income patients or are located in rural areas and other safety net providers that receive federal grant funding.

On May 14, 2018, HHS issued a request for information (RFI) to help the agency develop future policies to address high drug prices. HHS will formally publish the RFI in the Federal Register on May 16, 2018 and will allow 60 days for comments. The RFI largely mirrors the Administration’s blueprint issued last week in conjunction with President Trump’s speech on drug prices. See Baker Donelson’s Summary of Trump Administration Drug Pricing Blueprint.

The blueprint questioned whether growth in the 340B program has contributed to higher drug prices, stating that the “additional billions of dollars in discounted sales and the cross-subsidization necessary may have created additional pressure on manufacturers to increase list price[s].” President Trump also alluded to the 340B program in his speech, mentioning that his administration “reformed the Drug Discount Program for safety net hospitals to save senior citizens hundreds of millions of dollars on drugs this year alone.”

The RFI outlines actions the Administration may take to address high drug prices and poses questions related to other actions under consideration. HHS includes a discussion of the 340B program in the section listing other actions under review. Below is a summary of the questions raised related to 340B.

READ MORE


About the Authors

Sheila P. Burke
Washington, D.C.
202.508.3457
sburke@bakerdonelson.com

Nicole D. Carelli
Washington, D.C.
202.508.3451
niki@daschlegroup.com

Tiffani V. Williams
Washington, D.C.
202.508.3428
tiffani@daschlegroup.com

Jeffrey I. Davis
Washington, D.C.
202.508.3414
jeffdavis@bakerdonelson.com

Amit Rao
Washington, D.C.
202.508.3472
arao@bakerdonelson.com

www.bakerdonelson.com

Laboratory Compliance – Intent to Comply Insufficient to Avoid Medicare Enrollment Revocation

Robert Mazer | May 3, 2018

Honest Mistakes Can Result in Loss of Medicare Billing Privileges

For many compliance-related purposes, so-called legal “intent” is key in determining the consequences of an improper action.  An erroneous claim for payment can result in a simple claim for repayment, monetary penalties under the False Claims Act, or imprisonment depending upon whether it reflected an honest mistake, reckless disregard regarding the claim’s accuracy, or knowing and willful behavior.

Read more…